Zebra Technologies Corporation
ZBRA
$0.00
-2.14%
Zebra Technologies Corporation is a leading provider of automatic identification and data capture technology, operating in the Communication Equipment industry. The company is defined by its enterprise-focused solutions, holding a strong position in markets like retail, logistics, and manufacturing through its custom workflow optimization software and hardware.…
ZBRA
Zebra Technologies Corporation
$0.00
Related headlines
Investment Opinion: Should I buy ZBRA Today?
Based on a synthesis of the technical weakness, deteriorating fundamentals, and valuation metrics, the objective assessment points to a Hold rating for existing investors, with a Speculative Buy consideration only for deep-value, risk-tolerant investors. The stock is not suitable for conservative portfolios. The severe price decline has created a valuation opportunity, but the fundamental picture must show stabilization before a more confident Buy rating can be justified.
Sign up to view all
ZBRA 12-Month Price Forecast
The analysis yields a neutral stance with medium confidence. The valuation is compelling, but it is directly challenged by clear and significant fundamental deterioration. The path forward is highly dependent on the next few quarters' margin performance. The probabilities are weighted towards a base case of sideways consolidation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zebra Technologies Corporation's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
5 analysts
Implied Upside
—
vs. current price
Analyst Count
5
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for Zebra Technologies is limited, with only 5 analysts providing estimates. No consensus target price or ratings distribution data is available in the provided inputs. The available data includes estimated EPS and revenue averages for an unspecified future period, but insufficient information exists to summarize a clear analyst consensus on price targets or recommendations.
Bulls vs Bears: ZBRA Investment Factors
ZBRA presents a classic value trap versus deep value opportunity dichotomy. The stock is deeply oversold with a compelling forward P/E, but this is juxtaposed against severe and ongoing fundamental deterioration in margins and profitability. The strong free cash flow and enterprise market position provide a floor, but a turnaround is not yet evident in the financials.
Bullish
- Strong Free Cash Flow: Generated $831M TTM FCF, providing financial flexibility.
- Attractive Forward Valuation: Forward P/E of 10.4 suggests significant earnings recovery potential.
- Technically Oversold: Price is only 5% above 52-week low, indicating potential rebound.
- Enterprise Market Leadership: Strong position in retail, logistics, and manufacturing workflows.
Bearish
- Severe Profitability Compression: Q4 net margin collapsed to 4.75% from 12.22% YoY.
- Persistent Downtrend: Stock down 29% in 6 months, heavily underperforming the market.
- Liquidity and Leverage Concerns: Current ratio below 1 at 0.97, with D/E of 0.78.
- Gross Margin Pressure: Gross margin fell to 44.61% from 48.58% YoY.
ZBRA Technical Analysis
The stock has been in a pronounced downtrend over the observed period, with the price declining from around $295 in early October 2025 to approximately $209 by March 31, 2026. This represents a significant six-month decline of 29.33%, heavily underperforming the broader market which was down only 2.82% over the same period. Short-term performance remains weak, with the stock down 6.64% over the past month and 13.90% over the past three months. These declines also underperformed the S&P 500, which fell 5.25% and 4.63% over the same respective periods, indicating relative weakness. The current price of $209.08 is near the bottom of its 52-week range of $199.05 to $352.66, sitting just 5.0% above the 52-week low. This positioning suggests the stock is in a technically oversold area, though no RSI data was provided to confirm this condition.
Beta
1.66
1.66x market volatility
Max Drawdown
-41.6%
Largest decline past year
52-Week Range
$199-$353
Price range past year
Annual Return
-29.5%
Cumulative gain past year
| Period | ZBRA Return | S&P 500 |
|---|---|---|
| 1m | -10.0% | -4.3% |
| 3m | -18.3% | -4.0% |
| 6m | -33.5% | -2.0% |
| 1y | -29.5% | +22.2% |
| ytd | -18.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZBRA Fundamental Analysis
Revenue growth has shown volatility; the most recent Q4 2025 revenue of $1.475 billion grew 10.57% year-over-year, but this followed a sequential decline from Q3's $1.32 billion. Profitability has compressed significantly, with the Q4 2025 net margin at 4.75%, down sharply from 12.22% in Q4 2024, and operating margin falling to 15.05% from 16.87% over the same period. Financial health shows a debt-to-equity ratio of 0.78, indicating moderate leverage. The current ratio is 0.97, suggesting potential liquidity constraints as it is below 1. However, the company generated strong free cash flow of $831 million over the trailing twelve months, providing a solid cash cushion. Operational efficiency metrics have deteriorated. Return on Equity (ROE) stands at 11.68%, and Return on Assets (ROA) is 6.07%. The gross margin for Q4 2025 was 44.61%, a decline from 48.58% in the year-ago quarter, reflecting margin pressures.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.44%
Latest Quarter
Free Cash Flow
$831000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZBRA Overvalued?
Given the company has positive net income, the primary valuation metric used is the P/E ratio. The trailing P/E ratio is 29.45, while the forward P/E is significantly lower at 10.39, based on estimated future earnings. The Price-to-Sales (P/S) ratio is 2.29 and the EV/EBITDA is 15.26. Peer comparison data for industry averages is not available in the provided inputs. Therefore, a standalone assessment indicates the forward P/E of 10.4 suggests the market has priced in a significant earnings recovery, but the high trailing P/E reflects recent profit compression.
PE
29.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -202x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is the continuation of the severe margin compression witnessed in Q4 2025, where net income fell over 57% year-over-year despite revenue growth. This suggests significant operational or cost headwinds that may persist. Financial risk is elevated due to a current ratio of 0.97, indicating potential short-term liquidity constraints, though substantial TTM free cash flow of $831 million mitigates this somewhat. Market and execution risk is high, as evidenced by the stock's dramatic 41.6% drawdown and consistent underperformance versus the S&P 500. The high beta of 1.68 means the stock is highly sensitive to broader market downturns, which could exacerbate selling pressure. Finally, there is valuation model risk; the attractive forward P/E of 10.4 is predicated on a significant earnings recovery that may not materialize if margin pressures continue.
FAQ
The key risks are: 1) Continued profitability compression, as seen in the Q4 net margin drop from 12.2% to 4.8%. 2) Liquidity risk, with a current ratio below 1 at 0.97. 3) High volatility risk, with a beta of 1.68 causing amplified moves versus the market. 4) Execution risk in reversing the negative operational trends that have driven the stock's 41.6% drawdown from its high.
The 12-month outlook is for high volatility with a base case target range of $220-$260, representing modest upside from the current ~$209. The bull case (25% probability) sees a rally to $280-$320 on a successful turnaround, while the bear case (25% probability) could see a drop to $180-$200 if fundamentals worsen. The forecast is highly contingent on upcoming quarterly margin performance.
Based on forward earnings, ZBRA appears significantly undervalued with a forward P/E of 10.4, which is low for a technology company. However, based on trailing earnings (P/E of 29.5), it looks expensive, reflecting the recent profit collapse. The valuation is dichotomous; it is undervalued if earnings recover as implied, but could be fairly valued or overvalued if depressed margins persist.
ZBRA is a speculative buy only for risk-tolerant investors seeking a deep-value turnaround. The stock is down 29% in six months and trades near its 52-week low, with a forward P/E of 10.4 suggesting the market has priced in significant bad news. However, it is not a 'good buy' for most investors due to severe recent margin compression and ongoing fundamental deterioration that must reverse for the thesis to work.
ZBRA is unsuitable for short-term investment due to its high volatility and lack of a clear near-term catalyst. It may be suitable only for a long-term (3+ year) investment horizon for investors betting on a full operational turnaround. The deep value proposition requires time for management to execute a recovery in profitability, making it a patient, long-term speculative holding.